Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer
(2023) In European Urology Open Science 50. p.27-30- Abstract
Men with a low prostate-specific antigen (PSA) level (<1 ng/ml) in midlife may extend the rescreening interval (if aged 40–59 yr) or forgo future PSA screening (if aged >60 yr) owing to their low risk of aggressive prostate cancer (PCa). However, there is a subset of men who develop lethal PCa despite low baseline PSA. We investigated how a PCa polygenic risk score (PRS) in addition to baseline PSA impacts the prediction of lethal PCa among 483 men aged 40–70 yr from the Physicians’ Health Study followed over a median of 33 yr. We examined the association of the PRS with the risk of lethal PCa (lethal cases vs controls) using logistic regression adjusted for baseline PSA. The PCa PRS was associated with risk of lethal PCa (odds... (More)
Men with a low prostate-specific antigen (PSA) level (<1 ng/ml) in midlife may extend the rescreening interval (if aged 40–59 yr) or forgo future PSA screening (if aged >60 yr) owing to their low risk of aggressive prostate cancer (PCa). However, there is a subset of men who develop lethal PCa despite low baseline PSA. We investigated how a PCa polygenic risk score (PRS) in addition to baseline PSA impacts the prediction of lethal PCa among 483 men aged 40–70 yr from the Physicians’ Health Study followed over a median of 33 yr. We examined the association of the PRS with the risk of lethal PCa (lethal cases vs controls) using logistic regression adjusted for baseline PSA. The PCa PRS was associated with risk of lethal PCa (odds ratio per 1 standard deviation in PRS [OR] 1.79, 95% confidence interval [CI] 1.28–2.49). The association between the PRS and lethal PCa was stronger for those with PSA <1 ng/ml (OR 2.23, 95% CI 1.19–4.21) than for men with PSA ≥1 ng/ml (OR 1.61, 95% CI 1.07–2.42). Our PCa PRS improved the identification of men with PSA <1 ng/ml at greater risk of future lethal PCa who should consider ongoing PSA testing. Patient summary: A subset of men develop fatal prostate cancer despite having low prostate-specific antigen (PSA) levels in middle age. A risk score based on multiple genes can help in predicting men who may be at risk of developing lethal prostate cancer and who should be advised to have regular PSA measurements.
(Less)
- author
- organization
- publishing date
- 2023-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Lethal prostate cancer, Polygenic risk score, Prostate-specific antigen
- in
- European Urology Open Science
- volume
- 50
- pages
- 27 - 30
- publisher
- Elsevier
- external identifiers
-
- scopus:85148727943
- pmid:36861107
- ISSN
- 2666-1691
- DOI
- 10.1016/j.euros.2023.01.012
- language
- English
- LU publication?
- yes
- additional info
- Funding Information: Funding/Support and role of the sponsor: This study was funded by the Department of Defense (W81XWH-19-1-0708, M.A.P.) and the National Institutes of Health/National Cancer Institute (P30-CA008748, S.V.C and H.L.; K22-CA234400, S.V.C.). Physicians’ Health Study PSA data generation was supported by the Department of Defense (W81XWH-18-1-0158). The sponsor played a role in manuscript preparation. K.L.P., M.A.P., and R.E.G. are Prostate Cancer Foundation young investigators. The content is solely the responsibility of the authors and does not necessarily represent the official views of the sponsors. Publisher Copyright: © 2023 The Authors
- id
- e50ffb64-ebd0-4031-b7d4-2d3f511f3539
- date added to LUP
- 2023-03-16 18:11:29
- date last changed
- 2024-09-19 19:44:44
@article{e50ffb64-ebd0-4031-b7d4-2d3f511f3539, abstract = {{<p>Men with a low prostate-specific antigen (PSA) level (<1 ng/ml) in midlife may extend the rescreening interval (if aged 40–59 yr) or forgo future PSA screening (if aged >60 yr) owing to their low risk of aggressive prostate cancer (PCa). However, there is a subset of men who develop lethal PCa despite low baseline PSA. We investigated how a PCa polygenic risk score (PRS) in addition to baseline PSA impacts the prediction of lethal PCa among 483 men aged 40–70 yr from the Physicians’ Health Study followed over a median of 33 yr. We examined the association of the PRS with the risk of lethal PCa (lethal cases vs controls) using logistic regression adjusted for baseline PSA. The PCa PRS was associated with risk of lethal PCa (odds ratio per 1 standard deviation in PRS [OR] 1.79, 95% confidence interval [CI] 1.28–2.49). The association between the PRS and lethal PCa was stronger for those with PSA <1 ng/ml (OR 2.23, 95% CI 1.19–4.21) than for men with PSA ≥1 ng/ml (OR 1.61, 95% CI 1.07–2.42). Our PCa PRS improved the identification of men with PSA <1 ng/ml at greater risk of future lethal PCa who should consider ongoing PSA testing. Patient summary: A subset of men develop fatal prostate cancer despite having low prostate-specific antigen (PSA) levels in middle age. A risk score based on multiple genes can help in predicting men who may be at risk of developing lethal prostate cancer and who should be advised to have regular PSA measurements.</p>}}, author = {{Ma, Chaoran and Ericsson, Caroline and Carlsson, Sigrid V. and Lilja, Hans and Kibel, Adam and Graff, Rebecca E. and Plym, Anna and Giovannucci, Edward and Mucci, Lorelei A. and Preston, Mark A. and Penney, Kathryn L.}}, issn = {{2666-1691}}, keywords = {{Lethal prostate cancer; Polygenic risk score; Prostate-specific antigen}}, language = {{eng}}, pages = {{27--30}}, publisher = {{Elsevier}}, series = {{European Urology Open Science}}, title = {{Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer}}, url = {{http://dx.doi.org/10.1016/j.euros.2023.01.012}}, doi = {{10.1016/j.euros.2023.01.012}}, volume = {{50}}, year = {{2023}}, }